4. Which of the following statement is correct regarding velocity and speed of a moving body? (1 Point)
(a) Velocity of a moving body is always higher than its speed
(b) Speed of a moving body is always higher than its velocity
(c) Speed of a moving body is its velocity in a given direction
(d) Velocity of a moving body is its speed in a given direction
quantity
5. Displacement is a
(1 Point
O

Galileo was the first to notice that the moon has craters, valleys, and mountains. how might this have changed people's perception of the moon at the time?

Part a determine the magnitude of the x component of f using scalar notation. fx f x = nothing lb request answer part b determine the magnitude of the y component of f using scalar notation. fy f y = nothing lb request answer part c determine the magnitude of the z component of f using scalar notation. fz f z = nothing lb request answer provide feedback figure1 of 1a force vector acting on a ring attached to the ground is shown in the xyz space together with its x, y, and z components lying on the corresponding positive axes. the ring is located at the origin. force f is located in the first octant. f makes an angle of 60 degrees with its x component and an angle of 45 degrees with its y component. a force vector acting on a ring attached to the ground is shown in the xyz space together with its x, y, and z components lying on the corresponding positive axes. the ring is located at the origin. force f is located in the first octant. f makes an angle of 60 degrees with its x component and an angle of 45 degrees with its y component.

Asubject in a clinical research trial experiences a serious, unanticipated adverse drug experience. how should the investigator proceed, with respect to the irb, after the discovery of the adverse event occurrence? a. do not report the adverse drug experience to the irb since it is a common adverse experience.b. report the adverse drug experience to the irb only if there are several other occurrences.c. report the adverse drug experience as part of the continuing review report.d. report the adverse drug experience in a timely manner, in keeping with the irb's policies and procedures, using the forms or the mechanism provided by the irb.